| 1.7 0 (0.29%) | 06-10 11:29 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.8 | 1-year : | 3.41 |
| Resists | First : | 2.4 | Second : | 2.92 |
| Pivot price | 1.77  |
|||
| Supports | First : | 1.57 | Second : | 1.3 |
| MAs | MA(5) : | 1.72  |
MA(20) : | 1.88 |
| MA(100) : | 1.66 |
MA(250) : | 2.05 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.6 |
D(3) : | 21.6 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 5.55 | Low : | 0.97 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PYXS ] has closed above bottom band by 37.8%. Bollinger Bands are 34.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.78 - 1.79 | 1.79 - 1.8 |
| Low: | 1.62 - 1.63 | 1.63 - 1.64 |
| Close: | 1.68 - 1.7 | 1.7 - 1.71 |
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Tue, 09 Jun 2026
Number of shareholders of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Mon, 08 Jun 2026
Pyxis Oncology, Inc. - MLQ.ai
Fri, 05 Jun 2026
PYXIS ONCOLOGY INC (PYXS) Stock Price & Overview - ChartMill
Thu, 04 Jun 2026
PYXS: Mid-year data will highlight MICVO's efficacy and safety in head and neck cancer, supporting pivotal plans - TradingView
Sat, 16 May 2026
Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives - simplywall.st
Thu, 14 May 2026
Pyxis Oncology (PYXS) posts $23.3M Q1 loss and advances MICVO trials - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 22.1 (%) |
| Held by Institutions | 33.8 (%) |
| Shares Short | 1,810 (K) |
| Shares Short P.Month | 2,270 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | 0 % |
| Operating Margin | -600.3 % |
| Return on Assets (ttm) | -52 % |
| Return on Equity (ttm) | -121.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -1.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.33 |
| PEG Ratio | 0 |
| Price to Book value | 3.52 |
| Price to Sales | 7.88 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|